NGcGM3/VSSP in small cell lung cancer |
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer |
NGcGM3/VSSP in Metastatic melanoma |
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer |
NEUVITAL V Study |
NeuroEPO-Stroke. Phase I-II |
NeuroEPO-Ataxia-Adults-Phase III |
NeuroEPO – Type 2 Spinocerebellar Ataxia Phase I-II |
NeuroEPO in stroke |
NeuroEPO in patients with Parkinson disease stage II-III |
NeuroEPO in patients with Mild-Moderate Alzheimer's disease |
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
NeuroEPO in mild-moderate Alzheimer's disease |
NeuroEPO in healthy volunteers. |
NASVAC therapeutic vaccine study |
NASVAC Phase II Trial in patients with Chronic Hepatitis B Virus infection |
Nasalferon in COVID-19 |
Nasalferon in ARI |
Nasal recombinant human interferon alfa-2b in ARI |
NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II. |